Michael Barbella, Managing Editor09.09.23
MPO's top companies report almost made it to the top this past week.
But topping the magazine's top-rated feature (in page views) was a Medtech Makers interview about the factors medical device companies must consider when developing a neurostimulation device. In the interview, Jim Biggs, director of NPI Technical Solutions at Cretex Medical, outlines considerations developers should plan for and reveals the benefits of working with the right manufacturing partners.
Product news from Xenex and MicroVention also drove website traffic this was week, as did Laborie's $600 million purchase of Urotronic. The deal consists of an upfront cash payment of $255 million, and up to an additional $345 million in potential commercial and reimbursement milestone payments. Laborie will also make a $5 million strategic investment into GIE Medical, a clinical-stage company spun out of Urotronic.
Xenex Disinfection Services enticed cybervisitors to the site with FDA de novo authorization for LightStrike+, a high-intensity, broad-spectrum ultraviolet (UV) light robot. The authorization reportedly creates a new medical device product classification.
Not to be outdone, MicroVention Inc. amassed pageviews with the U.S. debut of the ERIC Retrieval Device ifor ischemic stroke treatment, an FDA-cleared product that delivers thrombus control inside and outside of the device, offers no clot integration wait-time to drive procedure efficiency, and offers versatile treatment options for thrombectomy.
But topping the magazine's top-rated feature (in page views) was a Medtech Makers interview about the factors medical device companies must consider when developing a neurostimulation device. In the interview, Jim Biggs, director of NPI Technical Solutions at Cretex Medical, outlines considerations developers should plan for and reveals the benefits of working with the right manufacturing partners.
Product news from Xenex and MicroVention also drove website traffic this was week, as did Laborie's $600 million purchase of Urotronic. The deal consists of an upfront cash payment of $255 million, and up to an additional $345 million in potential commercial and reimbursement milestone payments. Laborie will also make a $5 million strategic investment into GIE Medical, a clinical-stage company spun out of Urotronic.
Xenex Disinfection Services enticed cybervisitors to the site with FDA de novo authorization for LightStrike+, a high-intensity, broad-spectrum ultraviolet (UV) light robot. The authorization reportedly creates a new medical device product classification.
Not to be outdone, MicroVention Inc. amassed pageviews with the U.S. debut of the ERIC Retrieval Device ifor ischemic stroke treatment, an FDA-cleared product that delivers thrombus control inside and outside of the device, offers no clot integration wait-time to drive procedure efficiency, and offers versatile treatment options for thrombectomy.
